Association between serum endothelial cell-specific molecule 1 and cirrhotic cardiomyopathy

Lixia MA; Xinhuan WEI; Zhenhuan CAO; Jing ZHANG

doi:10.12449/JCH240614

Volume 40 Issue 6

Jun. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(6): 1156-1161

PDF( 699 KB)

Association between serum endothelial cell-specific molecule 1 and cirrhotic cardiomyopathy

DOI: 10.12449/JCH240614

Third Department of Liver Disease Center，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

Research funding:

Beijing Municipal Administration of Hospitals Incubating Program (PX2024061)

More Information

Corresponding author: ZHANG Jing， drzhangjing@163.com （ORCID： 0000-0002-3082-8330）
Received Date: 2023-12-26
Accepted Date: 2024-02-08
Published Date: 2024-06-25

Abstract

Abstract

Objective Cirrhotic cardiomyopathy （CCM） refers to cardiac dysfunction and electrophysiological disorder caused by liver cirrhosis and is closely associated with the prognosis of patients with liver cirrhosis. Endothelial cell-specific molecule 1 （endocan） can be used as a diagnostic marker for cardiovascular diseases， and it remains unclear whether it is involved in the pathogenesis of CCM. The aim of this study is to investigate the expression of serum endocan in patients with CCM and its possible role in the development of CCM. Methods This cross-sectional study was conducted among the patients with liver cirrhosis who were consecutively admitted to Beijing YouAn Hospital， Capital Medical University， from January 2019 to January 2021， and according to the presence or absence of CCM， the patients were divided into CCM group with 19 patients and non-CCM group with 106 patients. ELISA was used to measure the serum level of endocan， and its correlation with liver function and cardiac function was analyzed. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U rank sum test was used for comparison of continuous data with skewed distribution between two groups； the chi-square test was used for comparison of categorical data between groups. A Pearson or Spearman correlation analysis was used to investigate the correlation between indicators， and the receiver operating characteristic （ROC） curve was used to assess the CCM predictive model. Results The CCM group had a significantly higher expression level of serum Endocan than the non-CCM group （2.69±0.43 ng/mL vs 2.23±0.52 ng/mL， t=2.247， P=0.034）. The patients with compensated cirrhosis had a significantly lower expression level of serum endocan than those with decompensated cirrhosis （2.41±0.37 ng/mL vs 2.72±0.49 ng/mL， t=3.214， P=0.02）. In the CCM group， the serum level of endocan was positively correlated with Child-Pugh score （r=0.509， P=0.026） and MELD-Na score （r=0.484， P=0.036） and was negatively correlated with mean arterial pressure （r=-0.591， P=0.013） and mitral ratio of peak early to late diastolic filling velocity （r=-0.515， P=0.042）. The serum endocan had an area under the ROC curve of 0.658 （95%CI： 0.522～0.781） in predicting CCM， when the cut-off value was 2.61 ng/mL， the sensitivity was 67.1% and the specificity was 73.7%. Conclusion There is a certain association between serum endocan and CCM， and serum endocan may be involved in the pathogenesis of CCM.
- Liver Cirrhosis,
- Cardiomyopathies,
- Endocan

FullText(HTML)

References(25)

References

[1]	LIU HQ, NGUYEN HH, YOON KT, et al. Pathogenic mechanisms underlying cirrhotic cardiomyopathy[J]. Front Netw Physiol, 2022, 2: 849253. DOI: 10.3389/fnetp.2022.849253.
[2]	WANG WW, LI HY, WANG ZC, et al. Progress in the application of ultrasonic cardiogram in cirrhotic cardiomyopathy[J]. Clin J Med Offic, 2022, 50( 9): 900- 903. DOI: 10.16680/j.1671-3826.2022.09.07. 王微微, 李宏宇, 王忠超, 等. 超声心动图在肝硬化心肌病中应用进展[J]. 临床军医杂志, 2022, 50( 9): 900- 903. DOI: 10.16680/j.1671-3826.2022.09.07.
[3]	MØLLER S, LEE SS. Cirrhotic cardiomyopathy[J]. J Hepatol, 2018, 69( 4): 958- 960. DOI: 10.1016/j. jhep.2018.01.006.
[4]	MØLLER S, DANIELSEN KV, WIESE S, et al. An update on cirrhotic cardiomyopathy[J]. Expert Rev Gastroenterol Hepatol, 2019, 13( 5): 497- 505. DOI: 10.1080/17474124.2019.1587293.
[5]	LIANG SY, LIN Q, SONG JL, et al. Role of bile acids in cirrhosis-related cardiomyopathy[J]. J Clin Hepatol, 2022, 38( 10): 2383- 2386. DOI: 10.3969/j.issn.1001-5256.2022.10.035. 梁世洋, 林强, 宋俊良, 等. 胆汁酸在肝硬化心肌病中的作用[J]. 临床肝胆病杂志, 2022, 38( 10): 2383- 2386. DOI: 10.3969/j.issn.1001-5256.2022.10.035.
[6]	KIM JS, KO GJ, KIM YG, et al. Plasma endocan as a predictor of cardiovascular event in patients with end-stage renal disease on hemodialysis[J]. J Clin Med, 2020, 9( 12): 4086. DOI: 10.3390/jcm9124086.
[7]	TOSHIKUNI N, OZAKI K, GEORGE J, et al. Serum endocan as a survival predictor for patients with liver cirrhosis[J]. Can J Gastroenterol Hepatol, 2015, 29( 8): 427- 430. DOI: 10.1155/2015/153805.
[8]	BALTA S, BALTA I, MIKHAILIDIS DP. Endocan: A new marker of endothelial function[J]. Curr Opin Cardiol, 2021, 36( 4): 462- 468. DOI: 10.1097/HCO.0000000000000867.
[9]	CELIK ZE, DEMIR F, YONAR H, et al. Association of endocan expression with clinicopathological prognostic parameters in breast carcinoma[J]. Cancer Biomark, 2021, 32( 4): 471- 477. DOI: 10.3233/CBM-201026.
[10]	KECHAGIA M, PAPASSOTIRIOU I, GOURGOULIANIS KI. Endocan and the respiratory system: A review[J]. Int J Chron Obstruct Pulmon Dis, 2016, 11: 3179- 3187. DOI: 10.2147/COPD.S118692.
[11]	SENOCAK GNC, YAPCA OE, YILMAZ EPT, et al. May endocan be a new biomarker in the diagnosis of endometriosis?[J]. J Gynecol Obstet Hum Reprod, 2022, 51( 7): 102423. DOI: 10.1016/j.jogoh.2022.102423.
[12]	OKYAY K. Cardiac biomarkers in coronary slow flow: Endocan and omentin-1[J]. Turk Kardiyol Dern Ars, 2019, 47( 4): 249- 250. DOI: 10.5543/tkda.2019.14701.
[13]	BEHNOUSH AH, KHALAJI A, BAHIRAIE P, et al. Endocan as a marker of endothelial dysfunction in hypertension: A systematic review and meta-analysis[J]. Hypertens Res, 2023, 46( 10): 2388- 2399. DOI: 10.1038/s41440-023-01402-y.
[14]	DELEHEDDE M, DEVENYNS L, MAURAGE CA, et al. Endocan in cancers: A lesson from a circulating dermatan sulfate proteoglycan[J]. Int J Cell Biol, 2013, 2013: 705027. DOI: 10.1155/2013/705027.
[15]	ZUWALA-JAGIELLO J, PAZGAN-SIMON M, SIMON K, et al. Serum endocan level in diabetes mellitus of patients with cirrhosis and risk of subsequent development of spontaneous bacterial peritonitis[J]. J Physiol Pharmacol, 2019, 70( 3): 10.26402/jpp.2019.3.06. DOI: 10.26402/jpp.2019.3.06.
[16]	HEN J, JIANG L, YU X, et al. Endocan: a key player of cardiovascular disease[J]. Front Cardiovasc Med, 2022, 8. DOI: 10.3389/fcvm.2021.798699.
[17]	BALTA S, MIKHAILIDIS DP, DEMIRKOL S, et al. Endocan: A novel inflammatory indicator in cardiovascular disease?[J]. Atherosclerosis, 2015, 243( 1): 339- 343. DOI: 10.1016/j.atherosclerosis.2015.09.030.
[18]	HIROOKA Y. How can endocan be used as a specific biomarker of endothelial dysfunction in hypertension?[J]. Hypertens Res, 2024, 47( 3): 794- 795. DOI: 10.1038/s41440-023-01542-1.
[19]	HSU SJ, LIN TY, WANG SS, et al. Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats[J]. Eur J Clin Invest, 2016, 46( 6): 572- 580. DOI: 10.1111/eci.12636.
[20]	KLISIĆ A, KAVARIĆ N, ABENAVOLI L, et al. Is endocan a novel potential biomarker of liver steatosis and fibrosis?[J]. J Med Biochem, 2020, 39( 3): 363- 371. DOI: 10.2478/jomb-2019-0042.
[21]	YANG JH, SHENG SH, YANG QW, et al. Endocan silencing induces programmed cell death in hepatocarcinoma[J]. Oncol Lett, 2017, 14( 5): 5333- 5339. DOI: 10.3892/ol.2017.6857.
[22]	HUANG X, CHEN C, WANG X, et al. Prognostic value of endocan expression in cancers: Evidence from meta-analysis[J]. Onco Targets Ther, 2016, 9: 6297- 6304. DOI: 10.2147/OTT.S110295.
[23]	SCHWABL P, BUCSICS T, SOUCEK K, et al. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites[J]. Liver Int, 2015, 35( 9): 2121- 2128. DOI: 10.1111/liv.12795.
[24]	JR WTF. Endocan in hypertension and cardiovascular disease[J]. Angiology, 2014, 65( 9): 757- 759. DOI: 10.1177/0003319713514478.
[25]	VOIOSU AM, BĂLĂNESCU P, DAHA I, et al. The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy[J]. Rom J Intern Med, 2018, 56( 3): 182- 192. DOI: 10.2478/rjim-2018-0007.

Relative Articles

[1]	Journal of Hepatology｜Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis[J]. Journal of Clinical Hepatology, 2024, 40(8): 1537-1537. doi: 10.12449/JCH2408.gwqkjpwzjj1
[2]	Weiming DAI, Lungen LU, Xiaobo CAI. Association between liver sinusoidal endothelial cells and liver fibrosis[J]. Journal of Clinical Hepatology, 2023, 39(2): 419-423. doi: 10.3969/j.issn.1001-5256.2023.02.027
[3]	Longzhu HAI, Qiangfu HU, Xiaoyong LI, Peilei GUO, Lingwei YANG. Risk factors for myocardial injury after Nano-Knife surgery in patients with pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(12): 2787-2792. doi: 10.3969/j.issn.1001-5256.2022.12.019
[4]	Shiyang LIANG, Qiang LIN, Junliang SONG, Jingjie WANG. Role of bile acids in cirrhosis-related cardiomyopathy[J]. Journal of Clinical Hepatology, 2022, 38(10): 2383-2386. doi: 10.3969/j.issn.1001-5256.2022.10.035
[5]	LIAO XianHua, YE JunZhao, ZHONG BiHui. Pathogenesis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2406-2410. doi: 10.3969/j.issn.1001-5256.2020.11.002
[6]	Yu ZiYue, Lin Xin, Han Ying, Cui LiNa. Role of liver sinusoidal endothelial cells in liver regeneration and the development of liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(9): 2072-2074. doi: 10.3969/j.issn.1001-5256.2019.09.041
[7]	Pan Qi, Luo ChunHai, Ma WanLing, Qu YuanFei, Wang JianRu, Chen Lin. Specific magnetic resonance imaging of vascular endothelial growth factor-C targeted molecular probe and its clinical significance in a rat model of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(7): 1492-1496. doi: 10.3969/j.issn.1001-5256.2018.07.025
[8]	Wang YaJie, Chen LiPing, Shang ZhiYin, Yang JingMao, Ai YingChun, Cheng JiLin. Advances in the effect of B-type natriuretic peptide and its significance in patients with cirrhotic cardiomyopathy[J]. Journal of Clinical Hepatology, 2018, 34(5): 1111-1114. doi: 10.3969/j.issn.1001-5256.2018.05.040
[9]	Sha Liang, He JianBo, Li KeZhi, Chen Chuang, Huang Shan, Zhao YinNong, Lian Fang, Wu GuoBin. Influence of specific down-regulation of LKB1 expression on invasion and migration of hepatoma cells[J]. Journal of Clinical Hepatology, 2017, 33(5): 875-879. doi: 10.3969/j.issn.1001-5256.2017.05.016
[10]	Li Nan, Liu YingDi, Guo MingZhou, Liang Hao. Effect of adiponectin on hepatic stellate cell contraction induced by endothelin-1 and its mechanism of action[J]. Journal of Clinical Hepatology, 2016, 32(2): 307-311. doi: 10.3969/j.issn.1001-5256.2016.02.022
[11]	Yang MengYi, Xu XiangXin, Xin Jun. Research advances in the application of specific molecular probes for positron emission tomography in diagnosis of early-stage liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2273-2276. doi: 10.3969/j.issn.1001-5256.2016.12.009
[12]	Zhang ShiRong, Chen DongFeng. Research advances in cirrhotic cardiomyopathy[J]. Journal of Clinical Hepatology, 2016, 32(5): 1005-1008. doi: 10.3969/j.issn.1001-5256.2016.05.047
[13]	Yang YingZhuo, Kang Peng, Gao Jie, Xu ChunLin, Wang ShiMei, Wu Xia. Research progress in liver-specific miR-122 in regulating liver diseases[J]. Journal of Clinical Hepatology, 2014, 30(5): 473-477. doi: 10.3969/j.issn.1001-5256.2014.05.025
[14]	Wang ShanJuan, Zhang LiHang, Mao JunLing, Liu YanLi, Ren HaiFeng. Case report of a 2-year misdiagnosis and mismanagement of liver cirrhosis complicated by POEMS syndrome[J]. Journal of Clinical Hepatology, 2013, 29(5): 383-384.
[15]	Wang TianRan, Wang LanTian, Qu YuanQing, Gu Yu, Zou ZiYing, Chen Li. Comparative analysis of serum markers of cardiac function in a rabbit model of and human patients with obstructive jaundice [J]. Journal of Clinical Hepatology, 2013, 29(3): 227-229.
[16]	Peng JianPing, Sun KeWei, Wu YuNan, Zhang QianQian. Programmed cell death 1 expression on HBV-specific CTLs induced by dendritic cells in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(12): 926-929.
[18]	Zhang Wei, Zhang ShiLan, Wang HaiBin. Detection and significance of plasma procalcitonin and soluble intercellular adhesion molecule-1 in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2004, 20(1): 23-24.
[19]	Wei LiJing, Xu Wei, Wei LiQin, Niu ChunHui. Soluble intercellular adhesion molecule-1, Hyaluronic acid and their clinical signifieance in liver cirrhosis[J]. Journal of Clinical Hepatology, 2003, 19(4): 234-235.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (313) PDF downloads(27)

Association between serum endothelial cell-specific molecule 1 and cirrhotic cardiomyopathy

DOI: 10.12449/JCH240614

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Association between serum endothelial cell-specific molecule 1 and cirrhotic cardiomyopathy

DOI: 10.12449/JCH240614

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content